- Home
- CKPT vs TWIN Comparison
CKPT vs TWIN Comparison
Compare CKPT & TWIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- TWIN
- Stock Information
- Founded
- CKPT 2014
- TWIN 1918
- Country
- CKPT United States
- TWIN United States
- Employees
- CKPT N/A
- TWIN N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- TWIN Industrial Machinery/Components
- Sector
- CKPT Health Care
- TWIN Industrials
- Exchange
- CKPT Nasdaq
- TWIN Nasdaq
- Market Cap
- CKPT 214.4M
- TWIN 182.9M
- IPO Year
- CKPT 2017
- TWIN N/A
- Fundamental
- Price
- CKPT $3.61
- TWIN $11.58
- Analyst Decision
- CKPT Strong Buy
- TWIN
- Analyst Count
- CKPT 3
- TWIN 0
- Target Price
- CKPT $10.33
- TWIN N/A
- AVG Volume (30 Days)
- CKPT 2.4M
- TWIN 32.9K
- Earning Date
- CKPT 11-12-2024
- TWIN 02-05-2025
- Dividend Yield
- CKPT N/A
- TWIN 1.33%
- EPS Growth
- CKPT N/A
- TWIN N/A
- EPS
- CKPT N/A
- TWIN 0.68
- Revenue
- CKPT $47,000.00
- TWIN $304,470,000.00
- Revenue This Year
- CKPT N/A
- TWIN N/A
- Revenue Next Year
- CKPT $151,162.55
- TWIN N/A
- P/E Ratio
- CKPT N/A
- TWIN $17.78
- Revenue Growth
- CKPT N/A
- TWIN 6.98
- 52 Week Low
- CKPT $1.38
- TWIN $10.83
- 52 Week High
- CKPT $4.50
- TWIN $18.00
- Technical
- Relative Strength Index (RSI)
- CKPT 41.64
- TWIN 40.65
- Support Level
- CKPT $2.98
- TWIN $12.25
- Resistance Level
- CKPT $4.44
- TWIN $12.47
- Average True Range (ATR)
- CKPT 0.42
- TWIN 0.55
- MACD
- CKPT -0.10
- TWIN -0.13
- Stochastic Oscillator
- CKPT 25.66
- TWIN 19.00
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.